ReviewNeurologic clinics2018
Treatment of Myasthenia Gravis.
Review in Neurologic clinics, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06860633 (Treatment of Myasthenia Gravis Exacerbation or Crisis With Efgartigimod), which is not on this map. Cited by 119 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Treatment of Myasthenia Gravis Exacerbation or Crisis With Efgartigimod: A Single Arm, Open Label Prospective Cohort Study
Who cites it
119 citing papers in PubMed, 3 syntheses or guidelines pooled it, 231 citations in OpenAlex.
- Effects of respiratory muscle training on respiratory function and functional outcomes in patients with myasthenia gravis: a systematic review.Frontiers in neurology · 2025Pooled it
- Systematic review of the patient burden of generalised myasthenia gravis in Europe, the Middle East, and Africa.BMC neurology · 2024Pooled it
- Effects of acupuncture treatment for myasthenia gravis: A systematic review and meta-analysis.PloS one · 2024Pooled it
- Long-term safety, tolerability, and efficacy of subcutaneous efgartigimod PH20 in generalized myasthenia gravis: final results from a phase 3 open-label extension study (ADAPT-SC+).Frontiers in neurology · 2026Trial
- Changes in corticosteroid and non-steroidal immunosuppressive therapy with long-term zilucoplan treatment in generalized myasthenia gravis.Journal of neurology · 2025Trial
- ADAPT NXT: Fixed Cycles or Every-Other-Week IV Efgartigimod in Generalized Myasthenia Gravis.Annals of clinical and translational neurology · 2025Trial
- Effects of Plasma Exchange Combined with Immunoglobulin Therapy on Consciousness, Immune Function, and Prognosis in Patients with Myasthenia Gravis Crisis: A Prospective Randomized Test.Computational and mathematical methods in medicine · 2022Trial
- A Randomized Open-Labeled Trial of Methotrexate as a Steroid-Sparing Agent for Patients With Generalized Myasthenia Gravis.Frontiers in immunology · 2022Trial
- Trial
- Ravulizumab (ALXN1210) vs eculizumab in C5-inhibitor-experienced adult patients with PNH: the 302 study.Blood · 2019Trial
- Real-World Clinical Outcomes and Corticosteroid Tapering in Telitacicept-Based Therapy for Ocular Myasthenia Gravis: An Exploratory Analysis by Prior Treatment History.Brain and behavior · 2026Article
- A rare case of morphea following zilucoplan treatment for generalized myasthenia gravis.JAAD case reports · 2026Article
- Single-cell RNA-sequencing of myasthenia gravis reveals transcriptional heterogeneity and dysfunction of immune cell populations.International immunology · 2026Article
- Are you weary of illness? Coping and existential positioning in life with myasthenia gravis.Medicine, health care, and philosophy · 2026Article
- Comorbidities and Treatment Patterns in People With Myasthenia Gravis in Denmark, Finland and Sweden: A Population-Based Observational Study.Muscle & nerve · 2026Observational
- Azathioprine Toxicity in Patients With Myasthenia Gravis: A Single Center Experience.Muscle & nerve · 2026Article
- Bridging the gap between patient and physician perspectives on management of generalized myasthenia gravis: a Delphi consensus study.Orphanet journal of rare diseases · 2026Article
- Pharmacological and speech-language pathology management of dysphagia in patients with myasthenia gravis.Naunyn-Schmiedeberg's archives of pharmacology · 2026Review
- Advancing Care in Myasthenia Gravis: What Can We Learn From the Multiple Sclerosis Community?Neurology and therapy · 2026Article
- A Delphi consensus on integrating novel therapies into the management of generalized myasthenia gravis.Therapeutic advances in neurological disorders · 2026Article
59 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
Abstract
With specialized care, patients with myasthenia gravis can have very good outcomes. The mainstays of treatment are acetylcholinesterase inhibitors, and immunosuppressive and immunomodulatory therapies. There is good evidence thymectomy is beneficial in thymomatous and nonthymomatous disease. Nearly all of the drugs used for MG are considered "off-label." The 2 exceptions are acetylcholinesterase inhibitors and complement inhibition with eculizumab, which was recently approved by the US Food and Drug Administration for myasthenia gravis. This article reviews the evidence base and provides a framework for the treatment of myasthenia gravis, highlighting recent additions to the literature.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.